Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?

ABSTRACT: Background: The past two decades have witnessed significant growth in non-commercial research and development (R&D) initiatives, particularly for neglected diseases, but there is limited understanding of the ways in which they compare with commercial R&D. This study analyses costs, timelines, and attrition rates of non-commercial R&D across multiple initiatives and how they compare to commercial R&D. Methods: This is a mixed-method, observational, descriptive, and analytic study. We contacted 48 non-commercial R&D initiatives and received either quantitative and/or qualitative data from 13 organizations. We used the Portfolio to Impact (P2I) model's estimates of average costs, timelines, and attrition rates for commercial R&D, while noting that P2I cost estimates are far lowe

SUBMITTER: Vieira M 

PROVIDER: S-EPMC8063537 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature